Coronavirus News Roundup: AstraZeneca Reports Vaccine Data, Webcast Discusses Current Treatments

Article

Here’s a roundup of this week’s coronavirus-related news.

Coronavirus

According to the COVID Tracking Project, the latest totals for coronavirus disease 2019 (COVID-19) in the US have surpassed 12 million cases, with approximately 250,925 deaths, as of November 24. Additionally, approximately 88,000 individuals are currently hospitalized with COVID-19 in the US, reaching a new all-time high for the 15th consecutive day.1

This week, AstraZeneca reported interim data on efficacy for its COVID-19 vaccine candidate, AZD1222, and the Infectious Disease Society of America led a webcast on currently available treatment options.

Here’s a roundup of the latest coronavirus-related news:

AstraZeneca Reports COVID-19 Vaccine Met Primary Efficacy End Point

One vaccine dosing regimen for AZD1222 showed 90% efficacy, according to investigators at the University of Oxford.

Read the full results here.

Infectious Disease Society of America Webcast Discusses Available COVID-19 Treatments

Infectious Disease Society of America offered a look at the current treatment options for COVID-19 and stressed the need to maintain precautions to keep people safe.

Read more. 

MJH COVID-19 Coalition Surveyed on Mask Mandates, Vaccines, and More

As COVID-19 cases rise across the country, members of the MJH Life Sciences COVID-19 Coalition shared their perspectives on pandemic containment efforts.

Read more.

Looking at the Epidemiology of COVID-19 in Pediatrics

A new study examines the epidemiology of pediatric COVID-19 cases in a large cohort, Contemporary Pediatrics reported.

Read more.

Reference

1. The COVID Tracking Project. Data. November 24, 2020. Accessed November 25, 2020. https://covidtracking.com/data

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.